Advertisement
UK markets closed
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     
  • AIM

    771.53
    +3.42 (+0.45%)
     
  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     
  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     
  • Bitcoin GBP

    50,239.45
    +2,757.24 (+5.81%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     

The Worldwide Idiopathic Pulmonary Fibrosis Industry is Expected to Reach $4.7 Billion by 2027

Company Logo
Company Logo

Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The Global Idiopathic Pulmonary Fibrosis Market size is expected to reach $4.7 billion by 2027, rising at a market growth of 6.9% CAGR during the forecast period.

Idiopathic pulmonary fibrosis (IPF) refers to a type of chronic lung disease wherein the lungs' tissues thicken and stiffen with time. The brain and other organs do not receive adequate oxygen due to the thickening of lung tissues. This disorder causes scar tissue (fibrosis) to form in the lungs, preventing the lungs from adequately transporting oxygen into the bloodstream. People between the ages of 50 and 70 are most commonly affected by the condition. Idiopathic pulmonary fibrosis is a type of interstitial lung disease (commonly known as ILD), a group of lung disorders characterized by inflammation or scarring in the lungs.

Some of the growth catalysts for the market are increased demand for ideal drugs for treating idiopathic pulmonary fibrosis, and favorable reimbursement policies provided by manufacturers and insurance providers in some countries. In addition, the prevalence of the fibrotic disease is on the rise, growing elderly population, and technological breakthroughs in cancer screening and detection are the key trends of the industry. On the other hand, the lack of appropriate disease treatment alternatives, on the other hand, limits market expansion.

In addition, some of the growth factors for the Idiopathic Pulmonary Fibrosis market are the surge in demand for cost-effective pharmaceuticals and the development of improved treatment options and
an increase in the number of people who smoke cigarettes enhances market growth. However, the lack of therapeutic alternatives that can entirely cure the disease is expected to hamper the growth of the idiopathic pulmonary fibrosis market.

IPF affects about 100,000 people in the United States, according to the National Institutes of Health, and 30,000 to 40,000 new cases are discovered each year. IPF is expected to have a global incidence of 10.7 cases per 100,000 person-years in males and 7.4 cases per 100,000 person-years in females. Idiopathic pulmonary fibrosis is expected to affect 20 instances per 100,000 people in men and 13 cases per 100,000 people in women.

COVID-19 Impact Analysis

Coronavirus (COVID-19) was discovered in Wuhan, Hubei Province, China, in December 2019. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is spread between people.

The virus quickly spread across the globe after its discovery in Wuhan. Moreover, this virus causes a variety of symptoms in individuals, ranging from minor to severe. Fever, dry cough, and exhaustion are some of the most prevalent symptoms. Breathing difficulties or shortness of breath, chest pain or pressure, and lack of speech or movement are all dangerous signs. Further, the virus has a significant fatality potential in the elderly population. COVID-19 has been classified as a pandemic by the World Health Organization (WHO) as of March 11, 2020. In addition, only a few vaccinations have been approved for COVID-19 prophylaxis on an emergency basis. As a result, the most crucial approach to inhibit the development of this disease is social distance. Furthermore, numerous countries around the world have implemented state-wide lockdowns in order to maintain social distance.

Market Growth Factors:

The growing rate of Lung Cancer

The increased global prevalence of cancer, rising healthcare costs, and increasing diagnoses have resulted in a vast patient pool undergoing screening procedures. Lung cancer, for example, is the second most prevalent cancer in both women and men, and is expected to impact over 235,000 persons in the United States by 2020, according to the American Society of Clinical Oncology (2020). According to Globocan (Global Cancer Observatory), 64,804 new cases of cancer is expected to be reported in Germany year 2020. According to the research, lung cancer claimed the lives of over 50,000 people in the country, making it the leading cause of death from cancer.

Supportive medications and clinical trials

ADVERTISEMENT

IPF is a deadly disease that worsens over time and primarily affects the elderly with several comorbidities. Pirfenidone from Genetech and nintedanib from Boehringer Ingelheim Pharma are licensed pharmaceuticals for the treatment of IPF. These treatments help patients live longer by slowing the rate of lung function decline. Pirfenidone has been utilized in over 42,000 people around the world and has anti-fibrotic and anti-inflammatory characteristics. Both drugs are effective in slowing the progression of the condition.

A variety of medicines for IPF are now undergoing clinical testing. For example, MediciNova's Tipelukast is a tiny bioavailable molecule with anti-fibrotic and anti-inflammatory properties, that is designed to suppress gene expression and promote IPF. Interventional tests on the medication are currently in phase 2. Similarly, FibroGen's Pamrevlumab is an antibody-based treatment for IPF that is currently in phase 3 clinical trials.

Marketing Restraining Factor:

High cost of treatment and lack of awareness & qualified professionals

IPF is acknowledged to be one of the rare diseases, with a high healthcare expense that is disproportionate to the disease's prevalence. Because of the high cost of drugs and treatments for idiopathic pulmonary fibrosis, a majority of people are hesitant to use or continue taking them. As a result, the high cost of such treatments makes them unaffordable for people belonging to the low-income category.

In addition, many countries lack awareness and treatment options for IPF. Further, many countries still lack appropriate healthcare infrastructure that devoid their citizens of basic and advanced healthcare services. Considering these aspects, in spite of a large number of people suffering from IPF, a very low number of people get appropriate treatments. Further, many people work in an environment that forces them to breathe in the existence of dust like asbestos fibers, coal dust, silica dust, and metal dust. As a result, such people are more vulnerable to developing lung-related diseases. Hence, these factors are anticipated to slow down the growth of the overall Idiopathic Pulmonary Fibrosis Market during the forecasting period.

Drug Type Outlook

Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. In 2020, the Pirfenidone segment acquired the largest revenue share of the Idiopathic Pulmonary Fibrosis Market. This is due to the increased use of pirfenidone drugs such as Esbriet and Pirespa around the world. In experimental models of pulmonary fibrosis, this medication possesses a combination of anti-inflammatory, antioxidant, and antifibrotic properties, making it a promising drug with treatment potential for IPF.

Distribution Channel Outlook

Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. The Hospital Pharmacies segment acquired a significant revenue share of the Idiopathic Pulmonary Fibrosis Market in 2020. The main objective of a hospital pharmacy is to keep track of how pharmaceuticals are used in hospitals and other medical facilities. Moreover, these pharmacies help improve patient outcomes with the help of pharmaceutical selection, prescription, procurement, delivery, administration, and review.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2020, North America emerged as the leading region in the overall Idiopathic Pulmonary Fibrosis Market. This is due to the strong infrastructure for developmental research, the availability of substantial research funds, and the rise in government initiatives for idiopathic pulmonary fibrosis. Moreover, the region is witnessing a growing number of individuals with IPF, thereby boosting the growth of the regional market.

Cardinal Matrix - Idiopathic Pulmonary Fibrosis Market Competition Analysis

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the major forerunner in the Idiopathic Pulmonary Fibrosis Market. Companies such as AstraZeneca PLC, Boehringer Ingelheim International GmbH and Galapagos NV are some of the key innovators in Idiopathic Pulmonary Fibrosis Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr - 2021, Dec) Leading Players

Chapter 4. Global Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 Global Pirfenidone Market by Region
4.2 Global Nintedanib Market by Region

Chapter 5. Global Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 Global Retail Pharmacies Market by Region
5.2 Global Hospital Pharmacies Market by Region
5.3 Global Online Providers Market by Region

Chapter 6. Global Idiopathic Pulmonary Fibrosis Market by Region

Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

For more information about this report visit https://www.researchandmarkets.com/r/1a6kl3

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900